Singular Genomics Return On Asset vs. EBITDA
| OMIC Stock | USD 20.01 0.00 0.00% |
For Singular Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Singular Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Singular Genomics Systems utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Singular Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Singular Genomics Systems over time as well as its relative position and ranking within its peers.
Singular |
Singular Genomics' Revenue Breakdown by Earning Segment
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Singular Genomics. If investors know Singular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Singular Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (34.68) | Revenue Per Share | Quarterly Revenue Growth (0.12) | Return On Assets | Return On Equity |
The market value of Singular Genomics Systems is measured differently than its book value, which is the value of Singular that is recorded on the company's balance sheet. Investors also form their own opinion of Singular Genomics' value that differs from its market value or its book value, called intrinsic value, which is Singular Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Singular Genomics' market value can be influenced by many factors that don't directly affect Singular Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Singular Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Singular Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Singular Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Singular Genomics Systems EBITDA vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Singular Genomics's current stock value. Our valuation model uses many indicators to compare Singular Genomics value to that of its competitors to determine the firm's financial worth. Singular Genomics Systems is rated below average in return on asset category among its peers. It is rated below average in ebitda category among its peers . At present, Singular Genomics' EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Singular Genomics' earnings, one of the primary drivers of an investment's value.Singular EBITDA vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Singular Genomics |
| = | -0.24 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Singular Genomics |
| = | (86.5 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Singular EBITDA Comparison
Singular Genomics is currently under evaluation in ebitda category among its peers.
Singular Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Singular Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Singular Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Singular Genomics' change in net profit over the period of time. It can combine multiple indicators of Singular Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 139.5 K | 146.5 K | |
| Net Interest Income | 8.5 M | 8.9 M | |
| Interest Income | 9.7 M | 10.2 M | |
| Operating Income | -92.5 M | -97.1 M | |
| Net Loss | -83.4 M | -87.6 M | |
| Income Before Tax | -85.3 M | -89.6 M | |
| Total Other Income Expense Net | 9.2 M | 9.6 M | |
| Net Loss | -81.8 M | -85.9 M | |
| Net Loss | -85.3 M | -89.6 M | |
| Income Tax Expense | 10.4 M | 11 M | |
| Non Operating Income Net Other | 3 M | 3.1 M | |
| Change To Netincome | 15.8 M | 16.6 M | |
| Net Loss | (44.94) | (47.18) | |
| Income Quality | 0.78 | 0.89 | |
| Net Income Per E B T | 1.12 | 1.10 |
Singular Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Singular Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Singular Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Singular Genomics' important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in Singular Genomics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Efficient Frontier Now
Efficient FrontierPlot and analyze your portfolio and positions against risk-return landscape of the market. |
| All Next | Launch Module |
Use Investing Themes to Complement your Singular Genomics position
In addition to having Singular Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Impulse Thematic Idea Now
Impulse
Large corporations operating in retail, broadcasting, energy, airlines and telecom sectors. The Impulse theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Impulse Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
To fully project Singular Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Singular Genomics Systems at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Singular Genomics' income statement, its balance sheet, and the statement of cash flows.